A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

June 25, 2024

Primary Completion Date

July 15, 2024

Study Completion Date

December 30, 2025

Conditions
Prostate CancerCirculating Tumor CellLeukapheresis
Interventions
DEVICE

leukapheresis

Leukapheresis employs the density differential between leukocytes and other blood components to selectively separate leukocytes and return all other components of the blood to the patient. It can process multiple blood volumes in the body circulation, thereby enabling the concentration of nucleated cells to be significantly increased. The procedure is performed while maintaining no significant change in the patient's circulating blood volume, and it is a routine clinical procedure that is well tolerated and safe. CTC can be greatly enriched in a concentrated sample of leukocytes because it has a similar density to that of leukocytes and other nucleated cells. The density of CTCs is similar to that of nucleated cells, such as leukocytes, which enables their enrichment in single leukocyte concentrate samples.

Trial Locations (1)

Unknown

Renji Hospital, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT06469710 - A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients | Biotech Hunter | Biotech Hunter